<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ISOMETHEPTENE/DICHLORALPHENAZONE/ACETAMINOPHEN</span><br/>(i-so-meth'ep-tene/di-chlor-al-phen'a-zone/a-cet'a-min-o-phen)<br/><span class="topboxtradename">Isopap, </span><span class="topboxtradename">Duradrin, </span><span class="topboxtradename">Midrin, </span><span class="topboxtradename">Migratine<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic, nonnarcotic</span><br/><b>Prototype: </b>Isometheptene/dichloralphenazone/acetaminophen<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p> 65 mg</p>
<p><b>isometheptene mucate,</b> 100 mg
      </p>
<p><b>dichloralphenazone,</b> 325 mg
      </p>
<p><b>APAP</b> capsules
      </p>
<h1><a name="action">Actions</a></h1>
<p>Isometheptene is a sympathomimetic amine that acts by constricting cranial and cerebral arterioles.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Isometheptene relieves vascular headaches. Dichloralphenazone is a mild sedative that helps reduce headache pain. Acetaminophen
         is a mild analgesic.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Relief for tension, vascular, and migraine headaches.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients with glaucoma; severe renal disease, organic heart disease; hepatic disease; concurrent MAO inhibitors.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension; peripheral vascular disease, and recent cardiovascular attacks.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tension Headache</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12 capsules q4h up to 8 capsules/24 h<br/><br/><span class="indicationtitle">Migraine Headache</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2 capsules at onset, then 1 capsule qh until relief (max: 5 capsules/12 h)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give this drug to anyone who is concurrently using a <small>MAOI</small>. Allow 14 d to elapse between discontinuation of the <small>MAOI</small> and administration of this drug.
         </li>
<li>Do not give more than 8 capsules in a 24 h period.</li>
<li>Store at 15°30° C (59°86° F) in a dry place.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Transient dizziness. <span class="typehead">GI:</span> Acetaminophen hepatotoxicity. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">maoi</span>s may cause hypertensive crisis; other <b>acetaminophen</b>-containing drugs (including OTC) may increase risk of hepatotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed. <span class="typehead">Metabolism:</span> Dichloralphenazone is metabolized to chloral hydrate and antipyrine. See <small>ACETAMINOPHEN</small> and <small>CHLORAL HYDRATE</small> for more detail. <span class="typehead">Elimination:</span> Renal and hepatic. <span class="typehead">Half-Life:</span> 12 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP closely with preexisting hypertension.</li>
<li>Monitor lower extremity perfusion with a history of PVD.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid, or moderate, alcohol use while taking this drug.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Report any decrease in tolerance to walking if you have a history of PVD.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>